Navigation Links
VIA Pharmaceuticals Complies With NASDAQ Rule
Date:3/28/2008

and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

-- our ability to obtain necessary financing;

-- our ability to control our operating expenses;

-- our ability to recruit and enroll patients for the ACS and FDG-PET

clinical trials;

-- failure to obtain sufficient data from enrolled patients that can be

used to evaluate VIA-2291, thereby impairing the validity or

statistical significance of our clinical trials;

-- our ability to successfully complete our clinical trials of VIA-2291 on

expected timetables and the outcomes of such clinical trials;

-- complexities in designing and implementing cardiovascular clinical

trials using histological examinations, measurement of biomarkers,

medical imaging and atherosclerotic plaque bioassays;

-- the results of our clinical trials, including without limitation, with

respect to the safety and efficacy of VIA-2291;

-- the outcome of any legal proceedings;

-- our ability to obtain necessary FD
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
2. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
3. SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
4. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
5. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
6. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
7. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
8. SGX Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
9. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
10. LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series C Financing Round
11. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- Aridis is ... reached with Switzerland -based Kenta ... human monoclonal antibody (mAb) products, and technologies. This ... products for treatment of infections by common pathogens ... aureus , Pseudomonas aeruginosa , Acinetobacter ...
(Date:5/17/2013)... Toronto, Canada (PRWEB) May 17, 2013 ... to understanding complex biological systems that can help predict ... Keynote speaker Dr. Sergey Stepaniants, Head of Computational Biology ... of computational biology tools to ensure high-quality genomics when ... tools can be applied to complex data sets to ...
(Date:5/17/2013)... IAC Industries wants to share with you the success ... set up and furnish a research lab knowing that the ... year’s time. How does a company make choices in lab ... is efficient and cost-effective? , The solution was the ... planners at DisperSol determined that the concept of modular lab ...
(Date:5/16/2013)... Tampa, FL (PRWEB) May 16, 2013 ... has named Barbara A. Myers, CAE, to the ... Development. In her new role, Myers will be ... event development and production strategies, advancing the Society’s ... development processes and continuing to refine organizational, membership ...
Breaking Biology Technology:Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2
... JUPITER, Fla., May 12, 2011 Stem Cell Assurance, ... General Form for Registration of Securities on Form 10 pursuant ...  The Form 10 includes audited financial statements as of December ...  Based upon this filing, effective July 11, 2011, the Company ...
... 2011 The Maryland Academy of Sciences and the ... its Annual Awards which recognize the accomplishments of young ... Appelbaum, Associate Professor of Physics at the University of ... and Dr. Ganesh Sriram, Assistant Professor in the Department ...
... a private clinical-stage biotherapeutics company focused on the development ... today announced that key data from its Phase 2 ... with data from other JX-594 clinical trials, will be ... Therapy (ASGCT) Annual Meeting taking place May 18-21, 2011, ...
Cached Biology Technology:2011 Outstanding Young Scientist and Engineer Named; Baltimore City High School Students Awarded Glass Scholarships 2Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting 2Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting 3Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting 4
(Date:5/16/2013)... at MIT may someday eliminate the need for ... their blood-sugar levels and inject themselves with insulin. ... levels in the body and respond by secreting ... function of pancreatic islet cells, which are destroyed ... type of system could ensure that blood-sugar levels ...
(Date:5/16/2013)... discovered an ancient extinct creature with ,scissor hand-like, claws ... of his favourite movie star. , The 505 ... (pronounced Koo-ten-ee-che-la depp-eye), which is a distant ancestor of ... Depp for his starring role as Edward Scissorhands - ... unfinished creation, who has scissors for hands. , ...
(Date:5/16/2013)... in Cameroon and the manager of San Diego Zoo ... prestigious Whitley award. The Whitley award is an ... because it celebrates the extraordinary achievements of some of ... Abwe was selected for the award due to his ... and its wildlife inhabitants., HRH The Princess Royal, the ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3Actor Johnny Depp immortalized in ancient fossil find 2Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3
... academics from the University of Sheffield has shown for the ... skills and nutritional status of older people with dementia. ... Journal of Geriatric Psychiatry and funded by the National ... to assess the eating patterns of dementia patients in Taiwan. ...
... soils could play a part in the formation of the ... coast beaches in summer., A QUT team of scientists is ... iron-rich soil its red colour, reaches water to potentially contribute ... smell, but also make our eyes sting, cause fich kills ...
... in the body,s regulation of iron levels should provide a ... well as rare, potentially deadly iron overload, researchers said. ... of Blood that the protein neogenin, a receptor ... body,s interwoven regulatory process for iron. The receptor, located on ...
Cached Biology News:New method improves eating skills of dementia patients 2Is iron from soil a factor in algal blooms? 2Potential new target for drugs to treat iron deficiency and overload discovered 2
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
... contains 5 ml of DETACHaBEAD 19 ... Dynabeads CD19 (Pan B). B ... B) and released with DETACHaBEAD CD19 ... are suitable for applications such as ...
Request Info...
Porcine TNF-alpha/TNFSF1A ELISpot Development Module...
Biology Products: